Scandinavian ChemoTech Q4 2023: Initial take - Redeye

Redeye provides its initial comments on the Q4 2023 report from Scandinavian Chemotech. Sales was lower than we had foreseen, and OPEX was higher. We are encouraged to see the progress that has been made recently, including a positive alteration to the study design at AIIMS Jodhpur and the continued installation of devices in the US market. The cash balance was SEK0.9m at year-end.

Länk till analysen i sin helhet: https://www.redeye.se/research/988387/scandinavian-chemotech-q4-2023-initial-take?utm_source=finwire&utm_medium=RSS